Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro

Cancer Letters

Volumn 146, Issue 2, 1999, Pages 189-194

  Abdiu, Avni ^a   Larsson, Sven Erik ^a   Wasteson, Åke ^a   Walz, Thomas M ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cultured tumor cell; Fibrous histiocytoma; Platelet derived growth factor; Suramin

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; SURAMIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG SENSITIVITY; GROWTH STIMULATION; HUMAN; HUMAN CELL; MALIGNANT FIBROUS HISTIOCYTOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL DIVISION; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; PLATELET-DERIVED GROWTH FACTOR; SURAMIN; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0032721029     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00260-8     Document Type: Article

References (42)

1. Voogd T.E., Vansterkenburg E.L., Wilting J., Janssen L.H. Recent research on the biological activity of suramin. Pharmacol. Rev. 45:1993;177-203.
2. Gibson D.W. Histopathological studies on suramin toxicity in a chimpanzee. Tropenmed. Parasit. 28:1977;387-405.
3. Hawking F. Suramin: with special reference to onchocerciasis. Adv. Pharmacol. Chemother. 15:1978;289-322.
4. Tu S.M., Pagliaro L.C., Banks M.E., Amato R.J., Millikan R.E., Bugazia N.A., Madden T., Newman R.A., Logotheis C.J. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin. Cancer. Res. 4:1998;1193-1201.
5. Dawson N., Figg W.D., Brawley O.W., Bergan R., Cooper M.R., Senderowicz A., Headlee D., Steinberg S.M., Sutherland M., Patronas N., Sausville E., Linehan W.M., Reed E., Sartor O. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin. Cancer Res. 4:1998;37-44.
6. Bergan R.C., Walls R.G., Figg W.D., Dawson N.A., Headlee D., Tompkins A., Steinberg S.M., Reed E. Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. J. Natl. Med. Assoc. 89:1997;622-628.
7. Small E.J. Prostate cancer. Curr. Opin. Oncol. 9:1997;277-286.
8. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell. Biochem. 29:1985;265-273.
9. Coffey R.J. Jr., Leof E.B., Shipley G.D., Moses H.L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 132:1987;143-148.
10. Middaugh C.R., Mach H., Burke C.J., Volkin D.B., Dabora J.M., Tsai P.K., Bruner M.W., Ryan J.A., Marfia K.E. Nature of the interaction of growth factors with suramin. Biochemistry. 31:1992;9016-9024.
11. Gansler T., Vaghmar N., Olson J.J., Graham S.D. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J. Urol. 148:1992;910-914.
12. Minniti C.P., Maggi M., Helman L.J. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 52:1992;1830-1835.
13. Betsholtz C., Johnsson A., Heldin C.-H., Westermark B. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc. Natl. Acad. Sci. USA. 83:1986;6440-6444.
14. Baghdiguian S., Boudier J.A., Boudier J.L., Fantini J. Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. Cancer Lett. 75:1993;151-156.
15. Bojanowski K., Lelievre S., Markovitz J., Couprie J., Jacquemin-Sablon A., Kragh Larsen A. Suramin is an inhibitor of DNA topoisomerase II in vitro and Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3025-3029.
16. Gagliardi A.R., Taylor M.F., Collins D.C. Uptake of suramin by human microvascular endothelial cells. Cancer Lett. 125:1998;97-102.
17. Huang S.S., Koh H.A., Huang J.S. Suramin enters and accumulates in low pH intracellular compartments of v-sis-transformed NIH 3T3 cells. FEBS Lett. 416:1997;297-301.
18. Eisenberger M.A., Reyno L.M. Suramin. Cancer Treat. Rev. 20:1994;259-273.
19. Kuratsu J., Kurino M., Fukunaga K., Miyamoto E., Ushio Y. Stimulatory effect of suramin on the proliferation of human glioma cells. Anticancer Res. 15:1995;1263-1268.
20. Rubio G.J., Pinedo H.M., Virizuela J., van Ark-Otte J., Giaconne G. Effects of suramin on human lung cancer cell lines. Eur. J. Cancer, 31A. 1995;244-251.
21. Ramirez L.H., Julieron M., Bonnay M., Koscielny S., Zhao Z., Gouyette A., Munck J.N. Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model. Invest. New Drugs. 13:1995;51-53.
22. Morocz I.A., Lauber B., Schmitter D., Stahel R.A. In vitro effect of suramin on lung tumour cells. Eur. J. Cancer, 29A. 1993;245-247.
23. Cardinali M., Sartor O., Robbins K.C. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J. Clin. Invest. 89:1992;1242-1247.
24. Shin R., Naomoto Y., Kamikawa Y., Tanaka N., Orita K. Effect of suramin on human esophageal cancer cells in vitro and in vivo. Scand. J. Gastroenterol. 32:1997;824-828.
25. Frommel T.O. Suramin is synergistic with vinblastine in human colonic tumor cell lines: effect of cell density and timing of drug delivery. Anticancer Res. 17:1997;2065-2071.
26. Heldin C.-H., Westermark B., Wasteson Å. Platelet-derived growth factor: purification and partial characterization. Proc. Natl. Acad. Sci. USA. 76:1979;3722-3726.
27. Heldin C.-H., Bäckström G., Östman A., Hammacher A., Rönnstrand L., Rubin K., Nistér M., Westermark B. Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. EMBO J. 7:1988;1387-1393.
28. Hermansson M., Funa K., Hartman M., Claesson-Welsh L., Heldin C.-H., Westermark B., Nistér M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52:1992;3213-3219.
29. Smits A., Funa K., Vassbotn F.S., Beausang-Linder M., af Ekenstam F., Heldin C.-H., Westermark B., Nistér M. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am. J. Pathol. 140:1992;639-648.
30. Franklin W.A., Christison W.H., Colley M., Montag A.G., Stephens J.K., Hart C.E. In situ distribution of the β-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res. 50:1990;6344-6348.
31. Doolittle R.F., Hunkapiller M.W., Hood L.E., Devare S.G., Robbins K.C., Aaronson S.A., Antoniades H.N. Simian sarcoma onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science. 221:1983;275-277.
32. Waterfield M.D., Scrace G.T., Whittle N., Stroobant P., Johnsson A., Wasteson Å., Westermark B., Heldin C.-H., Huang J.S., Deuel T.F. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature. 304:1983;35-39.
33. Johnsson A., Betsholtz C., Heldin C.-H., Westermark B. Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. Nature. 317:1985;438-440.
34. Valgeirsdóttir S., Eriksson A., Nistér M., Heldin C.-H., Westermark B., Claesson-Welsh L. Compartmentalization of autocrine signal transduction pathways in sis-transformed NIH 3T3 cells. J. Biol. Chem. 270:1995;10161-10170.
35. Abdiu A., Walz T.M., Nishikawa B.K., Wingren S., Larsson S.E., Wasteson Å. Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur. J. Cancer. 34:1998;2094-2100.
36. Betsholtz C., Westermark B. Growth-factor induced proliferation of human fibroblasts in serum-free culture depends on cell-density and extracellular calcium concentration. J. Cell. Physiol. 118:1984;203-210.
37. Huang Y.Q., Li J.J., Nicolaides A., Zhang W.G., Friedman-Kien A.E. Increased expression of fibroblast growth factors (FGFs) and their receptor by protamine and suramin on Kaposi's sarcoma-derived cells. Anticancer Res. 13:1993;887-890.
38. 125I-epidermal growth factor binding to human meningeomas. Cell. Mol. Neurobiol. 13:1993;665-675.
39. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell. Biochem. 29:1985;265-273.
40. Baghdiguian S., Boudier J.L., Boudier J.A., Fantini J. Intracellular localisation of suramin, an anticancer drug, in human colonic adenocarcinoma cells: a study by quantitative autoradiography. Eur. J. Cancer. 32A:1996;525-532.
41. Lopez Lopez R., Peters G.J., van Loenen A.C., Pizao P.E., van Rijswijk R.E., Wagstaff J., Pinedo H.M. The effect of schedule, protein binding and growth factors on the activity of suramin. Int. J. Cancer. 51:1992;921-926.
42. Bos O.J., Vansterkenburg E.L., Boon J.P., Fischer M.J., Wilting J., Janssen L.H. Location and characterization of the suramin binding sites of human serum albumin. Biochem. Pharmacol. 40:1990;1595-1599.